{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:14:05Z","timestamp":1789992845229,"version":"4.0.1"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1097\/iae.0b013e3181c7018d","type":"journal-article","created":{"date-parts":[[2010,3,25]],"date-time":"2010-03-25T02:28:00Z","timestamp":1269484080000},"page":"S59-S62","source":"Crossref","is-referenced-by-count":16,"title":["DELAYED PRESENTATION OF CYTOMEGALOVIRUS RETINITIS IN AN INFANT WITH SEVERE CONGENITAL CYTOMEGALOVIRUS INFECTION"],"prefix":"10.1097","volume":"30","author":[{"given":"LORI E.","family":"COORS","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RAND","family":"SPENCER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210130","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0022-3476(03)00192-6","article-title":"Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial.","volume":"143","author":"Kimberlin","year":"2003","journal-title":"J Pediatr"},{"key":"R2-12-20210130","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/clinids\/13.2.315","article-title":"Summary of workshop on surveillance for congenital cytomegalovirus disease.","volume":"13","author":"Demmler","year":"1991","journal-title":"Rev Infect Dis"},{"key":"R3-12-20210130","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1086\/528376","article-title":"Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease.","volume":"197","author":"Kimberlin","year":"2008","journal-title":"J Infect Dis"},{"key":"R4-12-20210130","first-page":"31","article-title":"Congenital and perinatal CMV infections.","volume":"7","author":"Stagno","year":"1983","journal-title":"Semin Perinatol"},{"key":"R5-12-20210130","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/clinids\/20.3.665","article-title":"The National Congenital CMV Disease Registry Collaborating Group. Survelliance for CMV disease: a report from the National Congenital CMV Disease Registry.","volume":"20","author":"Istas","year":"1995","journal-title":"Clin Infect Dis"},{"key":"R6-12-20210130","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/01.inf.0000069767.43169.2d","article-title":"Treatment of children with congenital cytomegalovirus infection with ganciclovir.","volume":"22","author":"Michaels","year":"2003","journal-title":"Pediatr Infect Dis"},{"key":"R7-12-20210130","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00431-006-0192-2","article-title":"Selecting neonates with congenital cytomegalovirus infection for ganciclovir therapy.","volume":"165","author":"Smets","year":"2006","journal-title":"Eur J Pediatr"},{"key":"R8-12-20210130","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/j.semperi.2007.01.002","article-title":"Recent advances in the prevention and treatment of congenital cytomegalovirus infections.","volume":"31","author":"Adler","year":"2007","journal-title":"Semin Perinatol"},{"key":"R9-12-20210130","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1097\/01.inf.0000177280.28694.00","article-title":"Ganciclovir therapy for congenital cytomegalovirus infection in six infants.","volume":"24","author":"Tanaka-Kitajima","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"R10-12-20210130","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1136\/bjo.86.2.248","article-title":"Should active CMV retinitis in non-immunocompromised newborn babies be treated?","volume":"86","author":"Barampouti","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"R11-12-20210130","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0002-9394(99)00031-8","article-title":"Cytomegalovirus retinitis in immunosuppressed children.","volume":"127","author":"Baumal","year":"1999","journal-title":"Am J Ophthalmol"},{"key":"R12-12-20210130","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/00006454-199412000-00012","article-title":"Late onset and reactivation of chorioretinitis in children with congenital cytomegalovirus infection.","volume":"13","author":"Bobbana","year":"1994","journal-title":"Pediatr Infect Dis J"},{"key":"R13-12-20210130","first-page":"1633","article-title":"Retina. 4th ed.","author":"Vaudaux","year":"2006"},{"key":"R14-12-20210130","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0166-3542(00)00139-X","article-title":"Genetic risks of antiviral nucleoside analogues\u2014a survey.","volume":"49","author":"Wutzler","year":"2001","journal-title":"Antiviral Res"},{"key":"R15-12-20210130","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1177\/096032719701600905","article-title":"Ganciclovir induces reproductive hazards in male rats after short-term exposure.","volume":"16","author":"Faqi","year":"1997","journal-title":"Hum Exp Toxicol"},{"key":"R16-12-20210130","first-page":"364","article-title":"Treatment of symptomatic congenital cytomegalovirus infection with valganciclovir.","volume":"33","author":"Meine Jansen","year":"2005","journal-title":"J Perinat Med"},{"key":"R17-12-20210130","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/01.inf.0000261111.90075.4d","article-title":"Valganciclovir for congenital CMV infection: a pilot study on plasma concentration in newborns and infants.","volume":"26","author":"Galli","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"R18-12-20210130","article-title":"Whitley; National Institute of Allergy and Infectious Diseases (NIAID). Phase III, randomized, placebo-controlled, blinded investigation of six weeks vs six months of oral valganciclovir therapy in infants with symptomatic congenital cytomegalovirus infection (CASG 112). DMID Protocol Number: 06-0046; NCT00466817.","author":"Richard"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/IAE.0b013e3181c7018d","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:11:46Z","timestamp":1786039906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006982-201004001-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0b013e3181c7018d","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}